Case Western Collaboration

Evolutec Group PLC
24 May 2006


For immediate release                                             24 May 2006



                               EVOLUTEC GROUP PLC

                         ('Evolutec' or 'the Company')



                CASE WESTERN RESERVE UNIVERSITY  TO COLLABORATE

                             IN MYASTHENIA GRAVIS



Evolutec Group plc (AIM: EVC), the biopharmaceutical company developing novel
products for the treatment of allergic, inflammatory and autoimmune diseases, is
pleased to announce that Case Western Reserve University, Cleveland, Ohio, ('
Case') is to carry out further preclinical studies of rEV576, Evolutec's second
development candidate, in the auto-immune disease myasthenia gravis.  Evolutec
will provide the rEV576 and Case will provide the research funding.



The preclinical programme, which will consider the effectiveness of rEV576 as a
potential treatment for myasthenia gravis, will be undertaken during 2006 by
Professor Henry J. Kaminski, Case's Vice Chair of Neurology.



Professor Kaminski's interest follows the striking positive preclinical result
in myasthenia gravis announced by Evolutec in September 2005, in which a single
dose of rEV576 completely prevented paralysis and weight loss over a five day
period.



Myasthenia gravis, of which there are approximately 36,000 cases in the US,
results in progressive fatigue, loss of muscle tone and in severe cases
increasing paralysis.   There is no existing curative therapy for the condition,
and Evolutec has applied for Orphan Drug Status from the US Food and Drug
Administration.



Mark Carnegie Brown, Evolutec's Chief Executive Officer, commented: 'We are
delighted by Professor Kaminski's interest in rEV576.  Pending a successful
outcome of this collaboration and other preclinical programmes, we aim to
progress rEV576 to the clinic in 2007.'



Professor Henry J. Kaminski commented:  'I am excited about rEV576 as it appears
to have the qualities required to treat this debilitating and progressive
autoimmune disease.  I look forward to the results from this programme.'



                                      ENDS


For further information:
Evolutec                                                      0118 922 4480
Mark Carnegie Brown, Chief Executive Officer
Nicholas Badman, Chief Financial Officer
www.evolutec.co.uk

Buchanan Communications                                       020 7466 5000
Mark Court/Tim Anderson/Mary-Jane Johnson

Notes for Editors:

About Evolutec

Evolutec, which is based in Reading, UK, is a clinical stage biopharmaceutical
company with a focus on allergy, inflammation and auto-immune diseases.

The Company has completed a positive 112 patient proof of concept Phase IIa
clinical trial with rEV131, its lead product, in allergic rhinitis.  rEV131 met
the primary endpoint of reducing the sum of symptom scores at statistically
significant levels within 45mins of administration. Evolutec intends to complete
a further Phase IIb trial in allergic rhinitis and additional proof of concept
Phase II trials in post-cataract surgery and dry eye in 2006. Positive
pre-clinical data has also been generated in asthma. rEV131 is a histamine
binding protein that impacts the H1, H2 and recently discovered H4 histamine
receptor.  This mode of action gives rEV131 a unique product profile of reducing
both early and late stage inflammation.

The Company has a further two products in pre-clinical development: rEV598,
which is being evaluated in CINV (chemotherapy-induced nausea and vomiting), and
rEV576, a complement inhibitor indicated for treating reperfusion injury in
ischemic heart disease, stroke and cardiopulmonary bypass.

Evolutec is listed on the London Stock Exchange and develops therapeutics
originally isolated from the saliva of ticks. The tick remains undetected by its
hosts, including humans, by injecting an array of molecules into the skin that
suppresses host immunity. These stealth molecules have undergone millions of
years of natural evolution to select a promising efficacy, potency and safety
profile. Evolutec employs the tick's evolutionary stealth technology to offer
the potential of treating human diseases.

About Case

Case is among the US's leading research institutions. Founded in 1826 and shaped
by the merger of the Case Institute of Technology and Western Reserve
University, Case is distinguished by its strengths in education, research, and
service. Located in Cleveland, Case Western offers nationally recognized
programs in the Arts and Sciences, Dentistry, Engineering, Law, Management,
Medicine, Nursing, and Social Sciences.  Professor Kaminski is the recipient of
a National Institutes of Health ('NIH') grant to investigate new therapies for
myasthenia gravis.

Safe Harbour statement: this news release may contain forward-looking statements
that reflect the current expectations of the Company regarding future events.
Forward-looking statements involve risks and uncertainties. Actual events could
differ materially from those projected herein and depend on a number of factors
including the success of the Company's research strategies, the applicability of
the discoveries made therein, the successful and timely completion of clinical
studies, the uncertainties related to the regulatory process, the successful
integration of completed mergers and acquisitions and achievement of expected
synergies from such transactions, and the ability of the Company to identify and
consummate suitable strategic and business combination transactions.




                      This information is provided by RNS
            The company news service from the London Stock Exchange